These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [The role of dopaminagonists in the treatment of Parkinson's disease]. Ransmayr G Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084 [TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio. Espay AJ; Vaughan JE; Shukla R; Gartner M; Sahay A; Revilla FJ; Duker AP Mov Disord; 2011 Apr; 26(5):913-4. PubMed ID: 21432906 [No Abstract] [Full Text] [Related]
8. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Tousi B; Subramanian T Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966 [No Abstract] [Full Text] [Related]
9. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Varanese S; Howard J; Di Rocco A Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061 [No Abstract] [Full Text] [Related]
10. Current controversies: levodopa in the treatment of Parkinson's disease. Sharma JC; Vassallo M; Ross IN Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129 [No Abstract] [Full Text] [Related]
11. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]
12. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399 [No Abstract] [Full Text] [Related]
13. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335 [TBL] [Abstract][Full Text] [Related]
14. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
15. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945 [No Abstract] [Full Text] [Related]
16. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756 [TBL] [Abstract][Full Text] [Related]
17. [Physiopathology of the dyskinesias induced by L-dopa]. Grandas F; López-Ariztegui N Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682 [TBL] [Abstract][Full Text] [Related]
18. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease. Prashantha DK; Pal PK Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953 [No Abstract] [Full Text] [Related]
19. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606 [TBL] [Abstract][Full Text] [Related]
20. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease. Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084 [No Abstract] [Full Text] [Related] [Next] [New Search]